You are here: All Products  > iTabMed Approved to Start China Trials of CD3 Bi-specific for Solid Tumors

iTabMed Approved to Start China Trials of CD3 Bi-specific for Solid Tumors

Price: $5.00
Available

Get instant access to this article for unlimited viewing and/or downloading for seven days.


Back to products